Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
about
Synergistic effect of a novel oxymatrine-baicalin combination against hepatitis B virus replication, alpha smooth muscle actin expression and type I collagen synthesis in vitroClinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.Evolving therapies for the treatment of chronic hepatitis B virus infection.High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis BOutcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhoticsResistance to lamivudine therapy: is there more than meets the eye?trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report.Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment.Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology.Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant.Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.Viral features of lamivudine resistant hepatitis B genotypes A and D.Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
P2860
Q33868614-10D6D88F-C081-4A16-A68C-ADE91DABA13EQ34017787-04FB059A-7277-431B-BFCB-53A29251E4BBQ34519117-B7CD87DD-B46C-4BB4-B2B2-656A9F7FCE21Q35597143-1924FCCC-2FA5-47A0-91E7-BB4D22C108EAQ35615890-A5ECD557-3D40-418C-B154-BC712E6A89BDQ35980473-1043ABD8-3E25-4C08-B523-F8296BBBE10EQ36897030-DFA04F6C-CD13-4C32-91B2-612180F7280DQ37425703-F3606889-82C0-4CAB-88D1-A4BACED7CD24Q37511410-969EA596-7092-4FE2-AB6A-5546854D01A8Q40969094-0D8C6850-5029-424C-9750-C7440340FA21Q41653263-4B6281FB-4253-47B8-B8A5-7016571F881BQ42208973-60C0F8D8-4287-489A-BBE8-8D23CB98BC0BQ43005746-3AD5E251-B19C-414E-9B1B-FE5B00D14690Q43071697-AF91C0E4-5134-4428-AD4D-E06C960F4DF7Q43178380-DF66B2B8-5E04-464C-B30D-F5A10E18114BQ44159624-53E06E2B-489F-4FEA-BFCF-9383C769EB2EQ44646709-9321CDB4-7490-456B-B2BE-9C72F29B75DAQ44738460-D5C5362F-8342-4859-83D7-EAF4E7EAD84AQ44749272-D311A7F7-35F8-49EA-86EB-EA6B3983BBF1Q45441454-EE922EFD-C6C6-40C4-B80C-C85CFE0600E4Q46604917-1B1EC8FF-6950-4440-854B-E256AF787A8D
P2860
Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@en
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@nl
type
label
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@en
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@nl
prefLabel
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@en
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@nl
P2093
P356
P1476
Fatal submassive hepatic necro ...... long-term lamivudine therapy.
@en
P2093
P304
P356
10.1086/321879
P407
P577
2001-07-07T00:00:00Z